National Health Investors price target lowered to $72 from $78 at Truist

Truist analyst Michael Lewis lowered the firm’s price target on National Health Investors (NHI) to $72 from $78 and keeps a Hold rating on the shares. The firm is adjusting its model after the pullback in the stock price, though leaving its FFO multiple and net asset value premium relatively unchanged, the analyst tells investors in a research note. Truist adds it is positive on the REIT’s healthcare property type diversification, relatively high exposure to private payment for services from residents, a low-levered balance sheet, and an attractive well-covered dividend yield.